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To evaluate the role of 99mTc-DMSA (V) and [18F]FDG PET-CT in management of patients with osteosarcoma, 22 patients were
included in our study. All patients underwent both 99mTc-DMSA (V) and whole-body [18F]FDG PET-CT scans within an interval
of1week.555–740MBqof 99mTc-DMSA(V)wasinjectedi.v.thewhole-bodyplanar,SPECTimagesofprimarysiteandchestwere
performed after 3-4 hours. [18F]FDG PET-CT images were obtained 60 minutes after i.v. injection of 370MBq of F-18 FDG. Both
FDG PET-CT (mean SUVmax = 7.1) and DMSA (V) scans showed abnormal uptake at primary site in all the 22 patients (100%
sensitivity for both). Whole-body PET-CT detected metastasis in 11 pts (lung mets in 10 and lung + bone mets in 1 patient).
Whole-body planar DMSA (V) and SPECT detected bone metastasis in one patient, lung mets in 7 patients and LN in 1 patient.
HRCT of chest conﬁrmed lung mets in 10 patients and inﬂammatory lesion in one patient. 7 patients positive for mets on DMSA
(V) scan had higher uptake in lung lesions as compared to FDG uptake on PET-CT. Three patients who did not show any DMSA
uptake had subcentimeter lung nodule. Resuts of both 99mTc-DMSA (V) (whole-body planar and SPECT imaging) and [18F]FDG
PET-CT were comparable in evaluation of primary site lesions and metastatic lesions greater than 1cm. Though 99mTc-DMSA (V)
had higher uptake in the lesions as compared to [18F]FDG PET-CT, the only advantage [18F]FDG PET-CT had was that it could
also detect subcentimeter lesions.
1.Introduction
OS is a primary malignant bone tumor characterized by the
direct formation of immature bone or osteoid tissue by the
tumor cells. It is thought to arise from primitive mesenchy-
mal bone-forming cells. The classic OS is a rare (45% of all
malignant bone tumors) highly malignant tumor [1, 2], with
an estimated incidence of 3 cases/million population/year.
OSarisespredominantlyinthemetaphysisoflongbones,the
most common sites of involvement are femur (42%, 75% of
which are distal femur), tibia (19%, 80% of which are prox-
imal tibia), and humerus (10%, 90% of which are proximal
humerus). Other signiﬁcant locations are the skull and jaw
(8%) and pelvis (8%). The age at presentation ranges from
10 to 25 years of age.
The pretherapeutic diagnostic workup usually involves
physical examination, Radiological examination (plain radi-
ograph, computed tomography, magnetic resonance imag-
ing, angiography), radionuclide imaging (bone scintigraphy,
99mTc-DMSA (V), 18F-FDG-PET imaging), biopsy and lab
tests.
The aim of our study was to evaluate the role of Pentav-
alent 99mTc-Dimercaptosuccinic acid [99mTc-DMSA (V)]
and 18F-Fluoro-2-Deoxy-Glucose 18F-FDG PET-CT in the2 ISRN Oncology
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Figure 1: Graphs showing distribution of OS by age, sex, and anatomic site of distribution.
management of patients with osteosarcoma and to compare
results of 99mTc-DMSA (V) with 18F-FDG PET-CT scan in
these patients.
2.MaterialsandMethods
A total of 22 patients (14 males and 8 females) with
biopsy-proven OS were included in this study. Age of the
patients ranged from 8–66yrs (mean age = 22.2yrs). Pre-
or postchemotherapy patients (both the types of patients)
before surgery were included. Patients excluded were those
who had undergone surgery before the nuclear medicine
examinations and patients with diabetes mellitus or patho-
logic glucose tolerance. The patients with primary metastasis
disease were not excluded.
2.1. Radiopharmaceuticals. We used two types of imaging
modalities with two diﬀerent radiopharmaceuticals, 99mTc-
DMSA (V) for whole-body scintigraphy using gamma
camera and 18F-FDG for PET-CT imaging. 99mTc is a gamma
emitter and generator produced while 18Fi sap o s i t r o n
emitter and cyclotron produced.
2.2. PET/CT Data Acquisition Protocol. A f t e rf a s t i n gf o ra t
least 6hrs, verifying the serum glucose level (that should
be below 140mg/dL) and with patients in a resting state,
i naq u i e tr o o m ,ad o s eo f5 – 1 0 m C io f18F-FDG was
injected intravenously depending on the age and weight of
the patient. After a 45–60 minutes uptake period, patient
was placed into the scanner. Initial CT acquisition was done
without oral or intravenous contrast injection; followed by
PET scan. On the PET/CT scanner, CT scan acquisition was
performed on spiral dual slice CT with a slice thickness
of 4mm and a pitch of 1. Images were acquired using a
matrix of 512 × 512 pixels and pixel size of about 1mm.
After completing the CT, the table is moved towards the
ﬁeld of view of PET. After transmissions scan, 3D PET
acquisition was taken for 3–5 minutes per bed position for
5–7 bed positions depending on the patient length. PET data
was acquired using a matrix of 128 × 128 pixels, and PETISRN Oncology 3
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Figure 2: Graphs showing correlation between SUVmax of 18F-FDG with size of tumour and between T/NTmax and T/NTavg with size of
tumour.
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Table 1: Patient’s characteristics.
Characteristics No. of patients (%)
Total no. of patients 22
Sex
(i) Male 14 (63.6%)
(ii) Female 8 (36.4%)
Age
(i) Age range 8–66 years
(ii) Mean age 21.55 years
Prechemotherapy 19
Postchemotherapy 3
Primary site of osteosarcoma
(i) Femur 11 (50%)
(ii) Humerus 3 (13.6%)
(iii) Tibia 3 (13.6%)
(iv) Fibula 2 (9.1%)
Other sites
(i) Chest 1 (4.5%)
(ii) Clavicle 1 (4.5%)
(iii) Jaw 1 (4.5%)
No. of patients with lung
metastasis on CT 10
No. of patients having distant
metastases 1
acquisitionofthesameaxialrange,aswaswithCT,wastaken
with the patient in the same position on the table. Separate
scans of the primary site were taken if it was not coming in
the FOV of the whole-body PET-CT acquisition. CT-based
attenuation correction of the emission images was done.
3. Processing Protocol
The CT images were acquired and reconstructed using opti-
mized parameters for attenuation correction. Data obtained
from the CT acquisition was used for low noise attenuation
correction of PET emission data and for fusion of atten-
uation corrected PET images with the corresponding CT
images. After completion of PET acquisition, images were
reconstructedbyiterativemethodorderedsubsetexpectation
maximization (2 iterations and 8 subsets) with a ﬁlter
of 5mm. The reconstructed attenuation—corrected PET
images, CT images and fused images of matching pairs
of PET and CT images—was available for review in axial,
coronal, and sagittal planes and in maximum intensity
projections, three dimensional cine mode.
After image reconstruction, a region of interest (ROI)
was carefully drawn around the site of the abnormal FDG
uptake on lesion/s in the consequent 4–6 PET-CT scan slices.
The slice with a maximal FDG uptake in the ROI was chosen
for quantitative measurement of metabolic activity of the
tracer (SUV). From these ROIs, the SUV was calculated
according to the formula described below:
SUV =
Mean ROI activity

MBq/g

Injected dose

MBq

/Body weight

g
,( 1 )
whereas “MBq” is the mega-Becquerel and “g” is the grams.
3.1. 99mTc-DMSA (V) Scanning. Patients were injected with
15–20mCi of 99mTc-DMSA (V), depending upon the age
and weight of the patients. Dual head gamma camera was
used and whole-body scans were taken 3-4 hours after the
injection. SPECT images of the primary and the chest were
also taken. Spot views were also taken if needed.
3.2. Acquisition Protocol. Whole-body planar images were
acquired using the continuous mode with a table speed of
20cms/sec from head to toe. A matrix size of 256 × 1024 was
used. The photopeak was kept at 140keV with a 20% energy
window. Scan lengths were taken according to the length of
the patients.
SPECT Images of the Primary Site and Chest Region were
also Taken. SPECT images were taken with the following
protocol.
matrix size: 64 × 64,
frame time: 15–18sec/frame,
angular rotation: 3◦/frame,
circular orbit: 360◦.
3.3. Data Interpretation. Two experienced nuclear medicine
physicians evaluated the scan ﬁndings independently and
they were blinded to the structural imaging ﬁndings and
clinical ﬁndings. Images were looked for area of increased
radiotracer uptake and corresponding areas in the CT
images, and fused PET-CT images were corroborated.
3.4. Statistical Analysis. Multiple regression analysis was
performed to ﬁnd the signiﬁcance of correlation (r>0.5
and P<0.05 were considered signiﬁcant). The intensity
and the extent of uptake in 18F-FDG-PET-CT versus 99mTc-
DMSA (V) at the primary site were analysed quantitatively
and qualitatively. Accompanying lung lesions absent versus
present and their uptake imperceptible versus perceptible
were compared visually in both the modalities.
4. Results
In this prospective study a total of 22 patients were included.
All the patients were already biopsy-proven cases of OS.
All of them underwent thoracic CT within the two weeks
beforeorafter 18F-FDG-PET/CTand 99mTc-DMSA(V)scan.
Those patients who were taken after chemotherapy had
undergone therapy at least two weeks before the 18F-FDG-
PET/CT and 99mTc-DMSA (V) scan. Characteristics of all
patients are given in Table 1 with graphical representation in
Figure 1.
Age. In22patientsconsideredforthisstudy,rangeofagewas
8–66years,withameanageof22.2years.Maximumnumber
of patients falls within the range of 10–20 years, with 10
patients (45.5%) falling in this interval. Out of these patientsISRN Oncology 5
Table 2: Individual patient’s characteristics describing the age, sex, primary site involved, histopathological subtype, and metastatic
involvement of lung or any other site.
Patient no. Age (y) Sex Primary site Subtype Lung mets Other sites
1 48 F Rt Humerus N/A P N/I
2 16 M Rt Tibia MMT P N/I
3 13 F Rt Femur N/A N N/I
4 17 M Rt Humerus N/A P N/I
5 13 M Rt Femur N/A P N/I
6 24 M Rt Chest wall N/A N N/I
71 4 M L t F e m u r C D B N N / I
8 24 M Rt Femur N/A P N/I
9 66 M Rt Femur N/A P N/I
10 19 M Rt Femur Osteoclastic type P Left scapula
11 14 F Lt Clavicle CDB N N/I
12 25 M Rt Femur Spindle cells with necrosis
Osteoid+ NN / I
13 28 F Lt Humerus MMT N N/I
14 11 M Lt Femur MMT N N/I
15 35 F Lt Tibia MMT P N/I
16 8 F Lt Femur N/A P N/I
17 8 F Rt Femur N/A P N/I
18 24 M Lt Femur N/A N N/I
19 16 M Lt Tibia N/A N N/I
20 10 F Lt Fibula N/A N N/I
21 17 M Lt Fibula MMT N N/I
22 24 M Rt Jaw
Spindle cells
(freq. mitosis and high
labelling index, MIB-I)
NN / I
F: female, M: male, Rt: right, Lt: left, N/A: not available, CDB: chondroblastic diﬀerentiation, MMT: malignant mesenchymal tumor, P: positive, N: negative,
N/I: not involved.
maximum number of patients as males 8/10 (80%) and only
2/10 (20%) were females. Next higher number of patients,
as in the range of 20–30 years with 6/22 patients (27.3%),
including 5/6 (83%) males and 1/6 females (16.7%). Interval
of 1–10 years also included 3 patients (13.6%); all were >5
years in age with 100% females. Interval 30–40 years and
40–50 years included 1 patient (4.5%) each and both were
females. 50–60 years of interval included no patient. Another
interval of 60–70 years included 1 patient (4.5%), who was
male.
Sex. Out of 22 patients, 14 patients (63.6%) were males, 8
were females (36.4%). Male- to- female ratio was 1.74. Out
of14males,maximumnumberofmaleswasintheagegroup
of10–20years.Inhigheragegroupsof30–50,2females(9%)
out of 22 patients were diagnosed with OS.
4.1. Anatomic Site Distribution of OS. Of 22 patients, 11
patients had femur as primary site (10 cases (90%) of distal
femur and 1/11 patient (10%) of proximal femur), 3 patients
had humerus as primary site (with 100% proximal humerus
involvement), and 3 patient had tibial involvement of OS (all
the cases of proximal Tibia). 2 patients (9.1%) were having
ﬁbula inclusion (100% proximal ﬁbula). Other anatomic
locations were also diagnosed. Three patients were having
primary site of OS other than extremities. Out of these 3
(13.6%),1hadchestinvolvement(patient6),anotherpatient
had OS in clavicle (patient 11) and the last one was with
jaw involvement (patient 22) with each having a percentage
contribution of 4.5% to all the patients (Table 2).
4.2. 18F-FDG-PET-CT Findings
4.2.1. Primary Site. In all 22 patients, a baseline 18F-FDG-
PET-CT examination was performed without any chemo-
therapy or after a minimum of two weeks of chemotherapy;
the primary or residual tumor site demonstrated a clear or
moderate increased glucose uptake. Abnormal FDG uptake
was seen at the primary site in all the 22 patients showing the
involvement of the primary site. 18F-FDG-PET-CT showed
am e a no fS U V max = 7.104 ± 4.7( r a n g eo fS U V max = 2.2–
18.9) of the primary site. The details of individual 18F-FDG
uptake are given in all patients in Table 3. Since they were
already histopathologically proven, so the sensitivity of 18F-
FDG-PET-CT was 100% in detecting the primary site. No6 ISRN Oncology
Table 3: Showing the individual uptake values in case of both the 18F-FDG-PET/CT and 99mTc-DMSA (V).
18F-FDG-PET-CT 99mTc-DMSA (V)
Patient no. Primary site
SUVmax
Lung mets SUVmax T/NTmax primary site T/NTavg primary
site Lung mets L/Nmax Lung mets L/Navg
1 17.3 0.6 1.15 0.881 N N
2 18.9 0.5 7.04 6.054 5.313 3.081
3 11.4 N 4.06 0.349 N N
4 10.8 9.9 10.68 5.43 20.23 12.166
5 3.4 0.8 7.404 12.01 6. 214 3.633
6 6.6 N 3.64 3.72 N N
7 5.2 N 4.89 3.743 N N
8 4.3 1.3 5.7 4.324 2.89 2.689
9 4.1 0.5 3.098 3.226 N N
10 5.8 0.8 6.607 3.526 N N
11 5.7 N 4.01 3.346 N N
12 8 N 5.65 4.986 N N
13 2.2 N 2.19 2.06 N N
14 5.3 N 2.596 3.508 N N
15 15.5 2.0 3.889 3.088 1. 5 1.298
16 2.3 0.9 2.032 3.138 2.0 1.967
17 2.6 1.6 1.52 2.885 1.788 1.538
18 4.7 N 3.52 2.973 N N
19 7.8 N 2.667 4.958 N N
20 4 N 5.788 4.599 N N
21 4.3 0.6 3.536 2.947 N N
22 6.1 N 6.121 2.985 N N
correlation was found between the size of the tumor and the
SUVmax (r = 0.1209) (Figure 2(a)).
4.2.2. Metastases. Analyzing the results of whole-body 18F-
FDG-PET-CT scans each patient underwent, foci with
increased pulmonary/pleural tracer uptake was found in
11/22 patients. By correlating clinical and other imaging
ﬁndings, 10/11 (90%) of the examinations were classiﬁed as
true positive, one as false positive. Out of 11 patients, 8 had
b i l a t e r a ll u n gn o d u l ew i t hv a r i a b l ed e g r e eo fF D Gu p t a k e
(mean SUVmax = 1.1). One patient (patient 9) had bilateral
lung nodule with no FDG uptake in one nodule. The other
remaining two patients had solitary lung nodules (patients
1, 21). Out of these 2, “1” had mild [18F]FDG uptake while
theotherfoundtobeinﬂammatorylesiononHRCT(patient
21). So 18F-FDG-PET-CT was found to have a sensitivity
of 100% in detecting the lung mets and speciﬁcity of 91%
in comparison to the other clinical and imaging modalities
ﬁndings. Although PET alone was not able to detect many
lesions but with the incorporation of CT, sensitivity of PET
increased tremendously.
With regard to other metastatic locations, abnormal
uptakewasalsodetectedinonepatient(patient10)atthesite
of left scapula (coracoid process). No other abnormal uptake
was detected at any other site.
4.3. 99mTc-DMSA (V) Scan Findings. All the 22 patients un-
derwent 99mTc-DMSA (V) scanning within one week, before
or after, 18F-FDG-PET-CT scans.
4.3.1. Primary Site. Whole-Body planar imaging and SPECT
images of the primary site of OS in all the patients revealed
variable degree of uptake of 99mTc-DMSA (V) at the primary
tumor site. Large variation was seen in the tumor-to-
nontumor ratios (T/NTs). The mean of maximum T/NT
or T/NTmax Was Found to be 4.446 ± 2.27 (Ranging from
1.148–10.689). The mean value of T/Ntavg came out to be
4.125 (ranging from 1.881–12.01). Individual patient values
of T/NTmax and T/NTavg are given in Table 3.S o99mTc-
DMSA(V)showed 100% sensitivity in detecting theprimary
site like 18F-FDG-PET-CT ﬁndings. t/nts of 99mTc-DMSA
(V) showed no statistically signiﬁcant correlation with spect
to the size of the primary tumor. T/NTmax (r = 0.0311)
(Figure 2(b)) and T/NTavg (r = 0.2490) (Figure 2(c))w e r e
nowhere correlated to the size of the tumor. increased blood
pool activity was evident in all the scans, which decreased
with the delayed imaging.
4.3.2.Metastases. SpectofChestinallthepatientsweretaken
along with the whole body scans to detect the deep seated
metastasis. of all the 10/22 patients already proved to haveISRN Oncology 7
(a) (b)
(c)
Figure 4: Showing intense [18F]FDG uptake (a) and the 99mTc-DMSA (V) uptake (c) at the primary site of Rt humerus.
lung metastasis 7 patients (70%) showed abnormal uptake
in the lungs. increased uptake of 99mTc-DMSA (V) could be
easily identiﬁed as focal, sharply deﬁned regions with high
lesion-to-background ratio (L/N). the mean of maximum
lesion-to-background ratio (L/Nmax) was 1.8154 (1.5–20.23)
with patient 4 showing the highest value of 20.23. the mean
of average lesion-to-background ratio (L/Navg)w a sf o u n dt o
be 1.1987 (1.298–12.166) in 6 out of 7 patients. Intensity
of 99mTc-DMSA (V) uptake was either more (Figure 6)o r
comparable to the fdg uptake in 18F-FGG-PER-CT, while
one patient (patient 16) showed less uptake in comparison to
18F-FDG-PET-CT. patient 16 had large number of nodules
with intense fdg uptake on 18F-FDG-PET scan while 99mTc-
DMSA (V) showed only one lesion with less intensity of
uptake. Lesions in rest of the 3 patients were not detected on
the 99mTc-DMSA (V) scan. 3/10 patients (33%) (patient 1, 9,
10) who did not show any 99mTc-DMSA (V) uptake either
had sub centimeter lung nodule (patient 1 and 9) which
because of the limited resolution of gamma camera (0.9–
1.3cm) and the increased blood pool activity of 99mTc-
DMSA (V) in the major cardiovascular structures, were not
visible in spect or was post chemotherapy (patient 10) who8 ISRN Oncology
(a) (b)
(c)
Figure 5 :I n t e n s eu p t a k eo f[ 18F]FDG (a) and 99mTc-DMSA (V) (c) is seen at the primary site in the Rt femur along with the lung nodule in
the left lung lower lobe.
showed signiﬁcant response to the chemotherapy. also the
overall number of lung lesions detected with 99mTc-DMSA
(V) was less in all the 7 patients.
4.3.3. Other Sites. Abnormal uptake was also detected in
patient 10 in the left scapula region, as was seen in the 18F-
FDG-PET-CT images 99mTc-DMSA (V) could also show the
amount of necrosis and soft tissue involvement at primary
site. Patient 9 also showed uptake in the right axillary lymph
node. In case of children, there was an increased uptake at
the growth plates because of increased growth at these points
(patients 3, 5, 7, 11, 14, 16, 17, and 20).
4.3.4. SUVmax of 18F-FDG-PET-CT and T/NTs of 99mTc-
DMSA(V). Nostatisticallysigniﬁcantcorrelationwasfound
between SUVmax of 18F-FDG-PET-CT and the T/NTs ratios
of 99mTc-DMSA (V) of primary site with SUVmax and
T/NTmax (r = 0.2711, P = 0.2223), and SUVmax and T/NTavg
(r = 0.30, P = 0.18) (Figures 3(a) and 3(b)).
5. Discussion
OS is a rare form of bone cancers, which mainly aﬀects
the people in the age group of 10–25 years [3]. The 5-year
relative survival for children with bone cancer has improvedISRN Oncology 9
(a) (b)
(c) (d)
Figure 6: Showing the intense uptake in the left lung lower lobe nodule with higher intensity of uptake on 99mTc-DMSA (V) (d) than
[18F]FDG.
from 49% to 63% in the recent time with the development
of improved diagnostic modalities, which helps in the early
detection of disease. Early detection of the disease has good
prognosis. It usually metastasizes to the lungs and bones
which is associated with poor prognosis. So it is essential to
know about the metastatic involvement of the disease. In the
present study we tried to assess the role of 99mTc-DMSA (V)
indetectingtheprimaryaswellasthemetastaticinvolvement
of the OS by comparing it with the 18F-FDG-PET-CT.
Role of 18F-FDG-PET in characterizing the tumor as
malignant and benign has already been studied extensively
and it was found to be a promising tool to study the nature
of tumor noninvasively [4–7]. 99mTc-DMSA (V), which
is a tumor targeting radiopharmaceutical, has also found
application in detection of medullary thyroid carcinoma,
amyloidosis, head and neck cancers, and soft tissue tumors.
It was found to have higher sensitivity in detecting the bone
metastasis and soft tissue tumors than 99mTc-MDP[8, 9]. No
study has been done till now to compare the role of 99mTc-
DMSA (V) and 18F-FDG-PET-CT in imaging the primary
tumor of OS. However, one study which compared the
99mTc-DMSA (V), 99mTc-MDP, and CT found the scans of
99mTc-DMSA (V) superior to the 99mTc-MDP scans and the
CT scans in identifying the metastases of OS [10].
In our study we found that both the 18F-FDG-PET-
CT and 99mTc-DMSA (V) showed intense uptake at the
primary site in all the patients (Figures 4, 5,a n d7). 99mTc-
DMSA (V) showed equal sensitivity to 18F-FDG-PET in
detecting primary tumor sites. The extent of localization and
the intensity of uptake were comparable in both the cases.
Although no signiﬁcant statistical correlation was found
between the SUVmax and T/NT ratios of 18F-FDG and 99mTc-
DMSA (V), respectively. But the detection eﬃciency of the
two modalities was same. We found in our study that there
is no signiﬁcant statistical correlation between the SUVmax
or the T/NT ratios and the size of the primary tumors. This
couldbeduetotheassociationofprimarytumorsofOSwith
extensive tumor necrosis and calciﬁcation which causes the
nonuniform uptake of radiopharmaceutical.
18F-FDG-PET has also shown a higher sensitivity (98%)
indetectinglungmets,equivalenttoCT.Apositive 18F-FDG-
PET result can be used to conﬁrm any abnormalities seen
on thoracic CT scans as metastatic [11]. In our study 18F-
FDG-PET-CT showed 100% sensitivity in detecting the lung
mets. In case of 99mTc-DMSA (V) only 7 patients were found
to have lung mets. The decreased sensitivity of 99mTc-DMSA
(V) could be attributed to the limited resolution of gamma
camera (0.9–1.3cm) as most of the nodules, which were not
seen, were subcentimetre in size.
However, PET alone showed abnormal lung uptake
in 8 patients only out of 10 proved patients with lung
mets. This could be due to the partial-volume averaging
eﬀect (which is a reduction in detected activity that occurs
when the object size is smaller than the axial or transaxial
spacing) [12]. The signal of small lesions could be “diluted”
during reconstruction and malignant lesions can result in
false negative ﬁndings on PET images. Eﬀect of respiratory
motion is also well known to cause artifacts on PET images.
Although with the introduction of PET-CT, its sensitivity
has improved tremendously with the anatomic localization10 ISRN Oncology
(a) (b)
(c) (d)
Figure 7: Showing the uptake of both the [18F]FDG (b) and the 99mTc-DMSA (V) (d) in the primary at Rt jaw.
of various structures especially in case of evaluation of child-
hood sarcomas [13]. Similarly detection eﬃciency of 99mTc-
DMSA (V) can also be enhanced with the incorporation of
SPECT-CT.
In most of the cases, uptake in the normal bone was not
detectably greater than the surrounding soft tissue. In the
entire patients, both the excretion and retention in kidneys
were apparent, with excreted radioactivity exclusively in the
form of 99mTc-DMSA (V) [9], but the degree of retention
was variable. No area of increased uptake was noted in the
thyroid gland. Few females showed increased breast uptake.
Increased uptake in the liver was also seen in few patients.
Although no correlation was found between the extent of
disease and the renal and hepatic uptake, no correlation
could also be established between the extent of metastasis
and renal and liver uptake.
18F-FDG-PET has a disadvantage of showing a high
number of false positive results because of the increased
uptake in many inﬂammatory and benign nodules (as we
had one patient which had false positive uptake in theISRN Oncology 11
inﬂammatory ﬁbronodular lesion on 18F-FDG scan). Tumor
metabolism and, consequently tumor detection with 18F-
FDG-PET,maybehighlysusceptibletochemotherapy.While
99mTc-DMSA (V) is a tumor seeking agent and is not
metabolism dependent the extent of tumor uptake can
diﬀerentiate malignant and chondrogenic tumors. 99mTc-
DMSA (V) has an advantage of detecting bone as well as soft
tissue tumor [9, 14]. Although several instances of false-
positive uptake have occurred in both the soft-tissue as well
as skeletal disease but the lesions latter showed relatively low
uptake on bone scans. However, no false positive result was
obtained in our study with 99mTc-DMSA (V). We could also
detect abnormal uptake in bone mets at the scapula by both
the imaging modalities.
Apart from application in imaging tumors, interest in
the biodistribution of 99mTc-DMSA (V) is increasing these
days. Since the β-emitting analogues 186/188ReDMSA (V)
oﬀer the potential for targeted radiotherapy, the avidity with
which the tracer is taken up in most bone metastasis suggests
that this could be applied to palliative treatment [15].
Being a technetium labeled compound, 99mTc-DMSA
(V) is more economical and more accessible in comparison
to the 18F-FDG-PET-CT. There is no report of any false
positive uptake anywhere else in our study, which further
increases its reliability. So the use of 99mTc-DMSA (V) can be
thought over for scanning the patients with OS in detecting
the primary as well as the metastatic involvement at least in
those areas where 18F-FDG-PET-CT is not available.
6. Conclusion
Pentavalent 99mTcDimercaptosuccinic acid appears to be a
promising radiopharmaceutical for detecting primary and
metastases in patients with osteosarcoma. 18F-FDG PET-
CT also plays an important role in detecting primary and
metastases in these patients. When 99mTc-DMSA (V) is
compared with 18F-FDG-PET-CT, it has lower sensitivity
in detecting smaller metastatic lesions due to lower spatial
resolution of gamma camera as compared to PET-CT.
However, it requires costly setup including cyclotron, 18F-
FDG synthesizing cell and a PET/CT camera, thereby the
overall cost of an 18F-FDG-PET/CT scan is also more, which
m a yb ea sm u c ha s1 5t o2 0t i m e st h ec o s to fa99mTc- DMSA
(V) scan. Although 99mTc-DMSA (V) was not as sensitive
as 18F-FDG-PET-CT was, in detection of subcentimetre
nodules, but it seems to be an good alternative to 18F-FDG-
PET/CT in those areas where PET/CT is not available. Also,
thesensitivityof 99mTc-DMSA(V)scanmaybeimprovedfor
detection of sub centimeter nodules by using the SPECT-CT,
which further improves the anatomical location, keeping the
cost of scan still signiﬁcantly less compared to an 18F-FDG-
PET/CT scan.
99mTc-DMSA (V) also has another advantage over 18F-
FDG-PET/CT. The average whole-body dose delivered to the
patient in a 99mTc-DMSA (V) is found to be approximately
3mSv [16], while in a 18F-FDG-PET/CT scan, the average
dose delivered has been found to be 11-12mSv. Thus a
99mTc-DMSA (V) scan delivers 4 times less radiation dose to
the patient as compared to a 18F-FDG-PET/CT scan.
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